Reimbursement Review Reports

( Last Updated : April 2, 2015)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
Fabrazyme Agalsidase beta Fabry Disease Do not list Complete
Lyrica Pregabalin Pain, Neuropathic Do not list Complete
NovoMix 30 Insulin aspart/insulin aspart protamine Diabetes mellitus Do not list Complete
Macugen Pegaptanib sodium Macular degeneration, age-related Do not list Complete
Xolair Omalizumab Asthma, severe persistent Do not list Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Remodulin Treprostinil sodium Pulmonary arterial hypertension (NYHA Class III and IV patients) Do not list Complete
Hepsera Adefovir dipivoxil Hepatitis B Do not list Complete
Cipralex Escitalopram oxalate Depression, Major Depressive Disorder (MDD) Do not list Complete
Altace Plus Felodipine Ramipril/felodipine extended release Hypertension Do not list Complete